1British Committee for Standardsin Haematology, Blood Transfusion Task Force. Guidelines for the use of platelet transfusions. Br J Haematology, 2003, 122( 1 ) : 10-23.
2Slichter SJ, Davis K, Enright H, et al. Factors affecting posttransfusion platelet increments, platelet refractoriness, and platelet transfusion intervals in thrombocytopenic patients. Blood, 2005, 105(10) :4106-4114.
3Lin Y, Callum JL, Coovadia AS, et al. Transfusion of ABO-nonidentical platelets is not associated with adverse clinical outcomes in cardiovascular surgery patients. Transfusion, 2002, 42 (2) : 166- 172.
1Eder AF,Manno CS.Does red-cell T activation matter?[J].Br J Haematol,2001,114(1):25-30
2Molnar R,Johnson R,Sweat LT,et al.Absence of D alloimmunization in D-pediatric oncology patients receiving D-incompatible single-donor platelets[J].Transfusion,2002,42(2):177-182
3Asfour M,Narvios A,Lichtiger B.Transfusion of RhD-incompatible blood components in RhD-negative blood marrow transplant recipients[J].Med Gen Med,2004,6(3):22
4Cid J,Ortin X,Elies E,et al.Absence of anti-D alloimmunization in hematologic patients after D-incompatible platelettransfusions[J].Transfusion,2002,42(z):173-176
5Atoyebi W,Mundy N,Croxton T,et al.Is it necessary to administer anti-D to prevent RhD immunization after the transfusion of RhD-positive platelet concentrates?[J].Br J Haematol,2000,111(3):980-983
6Lozano M,Cid J.The clinical implications of platelet transfusions associated with ABO or Rh(D)incompatibility[J].Transfus Med Rev,2003,17(1):57-68
7Cooling LL.ABO and Human Blood Platelets[J/OL].Adv Administrators Lab,2004,13(3):72.http://laboratory-manager.advanceweb.com
